Horizon Therapeutics says daxdilimab trial did not show statistical significance

Horizon Therapeutics announced that its Phase 2 clinical trial evaluating daxdilimab for the treatment of SLE did not show a statistically significant separation between daxdilimab and placebo on the primary endpoint, which was the proportion of patients to achieve a British Isles Lupus Assessment Group, or BILAG, 2004 Index-based Combined Lupus Assessment, or BICLA, response and an oral glucocorticoid, or OGC, dose of less than or equal to 7.5 mg/day, which represented a reduction from the Baseline OGC dose at 48 weeks. BICLA is a composite measure indicating low SLE disease activity. Numerical differences were seen in other endpoints. No safety concerns were reported.